Skip to content

Mycobiome Supporting Diet to Reduce GI Toxicity Associated With ASCT

Mycobiome Supporting Diet (MSD) to Reduce Gastrointestinal (GI) Toxicity Associated With Autologous Stem Cell Transplant (ASCT) For Patients With Multiple Myeloma (MM)

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04685525
Enrollment
0
Registered
2020-12-28
Start date
2024-04-01
Completion date
2025-06-30
Last updated
2024-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autologous Transplant, Myeloma

Brief summary

The purpose of this study is to determine if this specific Mycobiome Supporting Diet (MSD diet) can help reduce gut inflammation during post-transplant period. The MSD is an special diet which will be explained in detail by a dietician that works by supporting the body's good gut bacteria and fungi.

Detailed description

This is a non-randomized cohort study. Participants will be on a specific diet for 4 weeks prior to transplant and 10 days after transplant, and will then be asked to fill out several questionnaires during this period to see if this diet is easy and simple to follow. The questionnaires will be weekly while participants are outpatient and once admitted to the hospital, participants will need to fill it on the last day (10 days after stem cell infusion). Participants will also be requested to provide fecal swab samples which we will test for bacteria and fungi. A total of 3 samples will be taken at different time points during this study.

Interventions

BEHAVIORALMycobiome Supporting Diet

MSD takes combines elements from several diets (e.g., Paleo, low-carbohydrate, vegetarian, and Mediterranean) and excludes elements of these diets that have been specifically proven to increase pathogenic fungi in the human gut.

Sponsors

Case Comprehensive Cancer Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Eligible for first autologous transplant for myeloma * Willing to adhere to the allowed and disallowed foods of the diet plan. * Able to get and prepare their own food items for all meals during the study

Exclusion criteria

* Active inflammatory bowel disease, celiac disease, other chronic intestinal disorders * Pregnant women, planning to get pregnant or breastfeeding * Prior bowel resection * Inability to tolerate the study diet due to allergies/ intolerance/ preference * Inability to consent to trial * Patients with restrictions in diet including inability to have oral nutrition with regular consistency * Any condition that the investigator feels may limit the volunteer's ability to complete the study protocol. * Patients with absolute neutrophil count (ANC) \< 1000 on long term antibacterial prophylaxis ongoing 3 days prior to enrollment * Patients who received antifungal therapy in 3 days prior to enrollment * Patients who received steroid therapy in 7 days prior to enrollment

Design outcomes

Primary

MeasureTime frameDescription
Percent of participants with at least 2 out of 3 assessments marked more than half the time on compliance questionnaire21 days prior to Transplant (an average of 1 month from start of study)MSD adherence feasibility measured by percent of participants with at least 2 out of 3 assessments marked more than half the time on compliance questionnaire. The questionnaire includes a multiple choice questions about adherence to diet (4 levels, from 'not at all' to 'the whole time'), a multiple choice question identifying barriers to adherence, and 8 yes/no questions about medication use and symptom experience. The MSD diet will deem feasible if at least 80 percent of participants showed adherence defined by 2 out of 3 assessment marked more than half the time.
Patient-reported outcome (PRO)-Common Terminology Criteria for Adverse Even CTCAE questionnaireAfter baseline (7 days post-transplant)Patient perception of symptoms measured using PRO-CTCAE questionnaire, consisting of 15 questions with frequency and severity scores, questions ranging 1 to 5, 5 is worse and 1 is less
PRO-CTCAE questionnaire scoresweek 1 in the 1 month prior to transplantPatient perception of symptoms measured using PRO-CTCAE questionnaire, consisting of 15 questions with frequency and severity scores, questions ranging 1 to 5, 5 is worse and 1 is less

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026